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Background: Many short peptides have proved to exhibit potential anti-hypertensive activity through the inhibition of
the Angiotensin I-converting enzyme (ACE) activity and the regulation of blood pressure. However, the traditional
experimental screening method for ACE inhibitory peptides is time consuming and costly, accompanied with the
limitations as incomplete hydrolysis and peptides loss during purification process. Virtual methods with the aid of
computer can break such bottle-neck of experimental work. In this study, an attempt was made to establish a
library of di- and tri-peptides derived from proteins of Phascolosoma esculenta, a kind of seafood, through BIOPEP
(http://www.uwm.edu.pl/biochemia/index.php/pl/biopep), and to screen highly active ACE inhibitory peptides by
molecular docking with the help of LibDock module of Discovery Studio 3.5 software.
Results: Two hundred and eighty four (284) di- and tri-peptides, derived from P. esculenta proteins after a virtual
hydrolysis with pepsin, trypsin and a mixture of pepsin and trypsin, were predicted to possess ACE inhibitory activity,
among which there are 99 ACE inhibitory peptides with estimated IC50 less than 50 μM. Nine peptides were synthesized
for the comparison between the estimated and the experimentally determined IC50. The results indicated that errors
between the estimated and measured log(1/IC50) are all less than 1.0 unit.
Conclusions: Virtual method for peptide library construction and ACE inhibitory peptides screening efficiently
demonstrated that P. esculenta proteins are prospect resource for food-origin ACE inhibitory peptide.
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Hypertension is a worldwide health problem, the preva-
lence of which have affected up to 30% of the adult
population according to the World Health Organization.
Hypertension carries a high-risk factor for arterioscler-
osis, myocardial infarction, and end-stage renal disease
[1,2]. It is predicted that by 2025, about 20% of the
world population will suffer from hypertension [3].
Although the cause of hypertension currently cannot
be well determined, it is understood that the renin-
angiotensin system regulates an organism's water, electro-
lytes, and blood, and the angiotensin I-converting enzyme
(ACE) (peptidyldipeptide hydrolase, EC 3.4.15.1) plays an* Correspondence: jlxie@ecust.edu.cn
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in any medium, provided the original work is pimportant role in regulating the blood pressure [4]. ACE
is a hypertension-responsible glycoprotein distributed in
vascular endothelial, absorptive epithelial, and male germi-
nal cells [5,6]. ACE cleaves the carboxyl terminal His-Leu
dipeptide from inactive decapeptide angiotensin I to
active angiotensin II, a powerful vasoconstrictor which
can trigger hypertension [7-10]. ACE also influences the
kallikrein-kinin system by promoting the degradation and
inactivation of bradykinin, which can lead to reduction of
hypertension. Therefore, excessive activity of ACE leads to
hypertension. Molecules which can inhibit the activity of
ACE are considered useful drugs for hypertension man-
agement [11]. Currently, synthetic ACE inhibitors, such as
captopril, enalapril and lisinopril, are available on the mar-
ket [12]; however, they tend to have side effects [13].
Since the discovery of the first anti-hypertensive pep-
tide in snake venom [14], more attention has been paid
to natural sources, especially peptides. Peptides derivedpen access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
Table 1 Properties of 22 P. esculenta proteins in UniProt
(http://www.uniprot.org/)
Name Number of amino acids MW (kDa) PI
D2J0B2 226 25.2 6.0
C3PUI4 378 43.2 9.1
D2J288 726 83.6 4.9
C3PUI8 304 34.6 8.5
C3PUI2 267 30.3 6.9
B6CQR3 658 71.6 5.1
A5A2J9 135 15.4 6.5
C3PUI5 121 13.9 6.7
B3TCX0 84 9.3 4.7
C3PUJ0 571 63.3 9.2
C3PUI9 231 25.7 5.9
B6CPA3 120 13.63 5.8
A5A2K2 220 24.4 5.8
C3PUH9 519 57.2 6.2
C3PUI7 450 50.2 9.2
B3TFG2 174 20.2 5.1
C3PUI1 54 6.5 10.8
C3PUI3 157 17.7 9.5
A3EX91 137 14.8 4.7
C3PUJ1 323 36.1 9.1
C3PUI0 231 25.9 4.8
C3PUI6 94 10.5 9.2
MW molecular weight, PI isoelectric point.
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[17], soy bean [18,19], corn gluten [20], insect protein
[21], peanut flour [22], and egg [23] have been proven to
inhibit the activity of ACE. However, few studies were
reported about their side effects [24,25]. Nutritionists
claim that peptides found in food are safer than ‘trad-
itional’ drugs, and they are promising synthetic drug
substitutes [26].
Among the ACE inhibitory peptides, shorter ones
(di- and tri-peptides) usually have significant advan-
tages over longer ones. They easily pass through blood
circulation system [27,28] and then reach action sites
faster without being hydrolyzed by digestive enzymes
during the gastrointestinal digestion [29,30]. For these
reasons, the present study focused on di- and tri-
peptides.
The discovery of ACE inhibitory peptides with poten-
tial anti-hypertensive effect is mostly based on experi-
ments, which require amounts of labors and funds.
Besides, the possible active peptides can not be totally
harvested due to the incomplete hydrolysis and peptides
loss in the purification by the experimental protocols.
Recently, as the computation simulation technology for
drug design and discovery of molecular interaction are
booming, the virtual screening or in silico experiment
may replace the traditionally experimental screening
of anti-hypertensive peptides to some extent. Computa-
tional approaches, which are based on computational
evaluation of interactions between receptor and ligand,
are proved feasible for virtual screening [31]. Molecular
docking is a powerful and a widely used tool in molecu-
lar simulation, which is approximated to a lock-and-key
process. The docking protocol is to ‘dock’ a ligand into
an active site of a receptor; then, the interactions be-
tween them were ‘scored’ to assess the potential bio-
activity of candidate compounds. The most advantage of
docking is its high-throughput screening in short time
with little cost [32].
In this study, an attempt was made to investigate the
ACE inhibitory activity of di- and tri-peptides derived
from Phascolosoma esculenta, a marine deposit-feeding
benthonic invertebrates, also a traditional seafood with
over 70% protein (dry weight) in Southeast China
[33,34]. Database of di- and tri-peptides derived from P.
esculenta were established, and their ACE inhibitory
activities were predicted by virtual hydrolysis and screening
method. Finally, di- and tri-peptides which have obvious
ACE inhibitory activity were synthesized for verifying the
validity of such virtual strategy.
Methods
Materials
There are 22 proteins of P. esculenta with the protein
messages including entry name and sequence obtainedfrom UniProt (http://www.uniprot.org/) (Table 1). They
were used as original materials for database of di- and
tri-peptides. With the help of BIOPEP (http://www.
uwm.edu.pl/biochemia/index.php/pl/biopep), the 22 pro-
teins were virtually hydrolyzed with pepsin, trypsin, and
a mixture of pepsin and trypsin.
Molecular docking experiments
LibDock, a module of Discovery Studio 3.5 software
(DS3.5, Accelrys, San Diego, CA, USA), was used for
molecular docking experiments. Scoring results (Lib-
Dock score) about ligand-receptor combination were
used as the final criterion to estimate the ACE inhibitory
activity of ligands. Based on a previous study [35], the
corresponding relationship between LibDock score and
IC50 was
LibDock score ¼ 10:063 log 1=IC50ð Þ þ 68:08 ;
where IC50 is 50% inhibitory concentration (in μM)
towards ACE. According to the LibDock score, ACE
inhibitory activity of ligands could be estimated.
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crystal structures was available in the Protein Data Bank
(PDB) (http://www.pdb.org), from where the three-
dimensional structure of ACE was imported [PDB:1O8A].
Before the docking procedure, water molecules were
removed and zinc ions were retained. The 284 di- and tri-
peptides derived from P. esculenta were used as ligands, of
which structures and energies were generated with Chem-
BioDraw software [36] and minimized with the CHARMM
program [37], respectively. Parameters used in the docking
process are shown in Table 2.
Synthesis of peptides
Five tri-peptides (GYF, WAL, AYF, GLR, and ILK) and four
di-peptides (FK, QF, EL, and HK) generated through in
silico hydrolysis of P. esculenta protein, with purity of 95%,
were synthesized by GL Biochem Co. Ltd. (Shanghai,
China) for IC50 testing.
Measurement of ACE inhibitory activity
The ACE inhibitory activity was measured according to the
method of Cushman and Cheung [38] with slightTable 2 Parameters for molecular docking experiments
performed with the LibDock of DS3.5
Parameter name Parameter value





Number of HPTPot 100
Docking tolerance 0.25
Docking preference User specified
Max hits to save 10
Max number of hits 100
Minimum LibDock score 100
Final score cutoff 0.5
Max BFGS steps 50
Rigid optimization False
Max conformation hits 30
Max start conformations 1,000
Steric fraction 0.10
Final cluster radius 0.5
Apolar SASA cutoff 15.0
Polar SASA cutoff 5.0
Surface grid steps 18
Conformation method Best
Minimization algorithm Do not minimize
Parallel processing Truemodifications. Ten milligram of the sample was dissolved
in 1 mL distilled water and then diluted to seven different
concentrations for ACE inhibitory measurements. Fifteen
microliters of the sample solution in certain concentration
(Seven different concentrations) were needed, which were
determined by the pre-experiment about ACE inhibition
ratio. The whole principle is that the concentration which
ACE inhibition ratio reaches 50% is included within the
concentration range. The concentrations for GYF, FK,
WAL, QF, and AYF are 10, 20, 30, 40, 50, 60, and
70 μg/mL, and for EL, GLR, HK, and ILK are 20, 40, 60,
80, 100, 120, and 140 μg/mL, respectively) and 15 μL
substrate hippuryl-L-histidyl-L-leucine (HHL) (8.3 mM
Hip-His-Leu in 50 mM sodium borate buffer containing
0.5 M NaCl at pH 8.3) were mixed together and then pre-
incubated at 37°C for 5 min. The reaction was initiated by
adding 5 μL of ACE solution (310 mU/mL) and incubated
for 60 min at the same temperature. The reaction was
terminated by the addition of 1.0 M HCl (200 μL). Ten
microliters of the reaction solution was injected directly
onto a Thermo BDS-C18 column (3.0 mm× 250 mm,
5 μm, Thermo Scientific Co. Ltd., Waltham, MA, USA).
The mobile phase consisted of 10% acetonitrile and 90%
water with 0.1% trifluoroacetic acid (TFA). The flow rate
was 0.7 mL/min and the absorbance was monitored at
228 nm. All determination was carried out at least in
triplicate. The inhibition activity was calculated using the
following equation:
ACE inhibition %ð Þ ¼ 1− Ainhibitor=Acontrolð Þ½   100 ;
where Ainhibitor is the absorbance with ACE, HHL, and
sample, and Acontrol is the absorbance of hippuric acid (HA)
with ACE and HHL without the sample. Dose-dependent
ACE inhibition was investigated using at least five different
concentrations of peptides. The concentration of peptides
that inhibited ACE activity by 50% (IC50) was calculated
using a non-linear regression from a plot of ACE inhibition
versus sample concentrations.
Study on structural-active relationship of ACE inhibitory
peptides
The chemical properties of C-terminal and N-terminal
amino acids of 99 peptides with estimated IC50 less than
50 μM were summarized to deduce the structural-active
relationship of ACE inhibitory peptides.
Results and discussion
Pool of di- and tri-peptides derived from P. esculenta proteins
Pepsin, trypsin, and the mixture of pepsin and trypsin
were used to virtually hydrolyze the 22 proteins from P.
esculenta, with the help of BIOPEP (http://www.uwm.edu.
pl/biochemia/index.php/pl/biopep). In total, 2,667 peptides
were virtually produced, and among them, 1,084 were di-
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After excluding the repeated ones, there were 1,017 non-
repeated peptides, among which 284 were di- and tri-
peptides. The sequences and the frequencies of these 284
short peptides are shown in Table 3. These 284 peptides
were used as the ligands for docking experiment with ACE.Estimated IC50 distribution of ACE inhibitory di- and
tri-peptides
The estimated ACE inhibitory IC50 of the 284 di- and tri-
peptides derived from P. esculenta proteins were obtained
according to LibDock scores, which were summarized in
Figure 2. Ninety-nine (99) peptides had an estimated IC50
less than 50 μM (34.9% of 284 peptides), 100 peptides had
an estimated IC50 between 50 and 100 μM (35.2% of 284
peptides), and 37 peptides had an estimated IC50 less than
500 μM, accounting for 13.0%. Most reported ACE inhibi-
tory peptides with IC50 less than 100 μM showed potent
in vivo anti-hypertensive activity [39]. Therefore, P. escu-
lenta is a prospective anti-hypertensive peptide-containing
resource since more than two thirds di- and tri-peptides
theoretically possess obvious ACE inhibitory activity. The
sequences and estimated IC50 of di- and tri-peptides with
estimated IC50 less than 50 μM are shown in Table 4.
Short peptides were usually used for predicting potent
ACE inhibitory activity. Pripp docked 58 di-peptides into
protein target using the Molegro Virtual Docker version
1.1.1 software and found significant relationship between
docking results and experimental IC50 values [32]. Several
tri-peptides consisting of I or L and positive charged amino
acids and aromatic amino acids were synthesized, and their
ACE inhibitory activities were measured to clarify the
amino acid sequence for inhibition of ACE [40]. Larger
peptides, for instance, the sequence length more than 5,

















































Figure 1 Length distribution of peptides derived from P. esculenta prot
pepsin, trypsin, and a mixture of pepsin and trypsin.were reported with lower R2 (coefficient of variation)
because of the complexity in the modeling due to the
bigger peptide [42,43].Confirmation of virtual screening method
In order to confirm the validity of virtual screening method
of the present work, nine peptides were synthesized for
IC50 testing. The sequences of these peptides were obtained
from P. esculenta protein through virtual hydrolysis and
screening by docking experiments. The estimated log(1/
IC50) and measured log(1/IC50) of the nine peptides were
compared (Table 5). The error between the estimated log
(1/IC50) and measured log(1/IC50) is less than 1.0 unit.
Desirable limit for model is that the error between
estimated log(1/IC50) and measured log(1/IC50) is less than
1.5 units [30]. A reported quantitative structure-activity
relationship (QSAR) model was constructed on 168 di-
peptides and 140 tri-peptides collected from literatures, and
the model verification was made on seven reported di-
peptides and tri-peptides (not included in 168 di-peptides
and 140 tri-peptides), of which the error was between 0.07
and 1.39 [29]. On the ground of such criterion, the present
model is efficient and credible.
Previous studies suggested that the structural-active
relationship of ACE inhibitory peptides largely depended
on their amino acid composition, sequence, and configur-
ation, though the full mechanism of interaction between
peptides and ACE is not established so far [44,45]. For the
short peptides as di- and tri-peptides, the amino acid
composition and configuration are more significant. The
di- and tri-peptides which have an estimated IC50 within
50 μM were used to study the structural-active relationship
of these ACE inhibitors.
There are four kinds of C-terminal residues for 99






























eins by virtual hydrolysis. The enzymes used in virtual hydrolysis are
Table 3 Sequence and frequency of di- and tri-peptides derived from P. esculenta proteins by virtual hydrolysis
Peptide Frequency Peptide Frequency Peptide Frequency Peptide Frequency
ADL 1 GYF 2 NDK 2 STL 2
AEF 2 HAQ 2 NF 10 SVF 2
AEK 1 HER 1 NGK 1 SVL 4
AEL 2 HF 9 NIL 2 SWK 2
AF 19 HGL 2 NK 2 SWL 2
AGF 2 HIK 2 NL 13 SYL 1
AIF 4 HK 4 NLK 1 TAL 2
AK 2 HKF 1 NMR 1 TDK 1
AL 35 HL 17 NPF 6 TDR 1
ALR 1 HSL 2 NR 2 TEF 2
AMF 2 HTK 1 NRF 2 TF 7
APF 2 HTL 1 NSF 2 TGF 2
AQF 2 IAR 2 NTL 3 TGL 4
AR 2 ICL 4 NVL 5 TIL 2
ASK 1 IF 20 NVR 2 TK 4
AVK 2 IGR 1 NWL 2 TL 31
AVR 2 IHR 2 PCK 1 TLK 1
AYA 2 IIL 4 PDL 2 TML 2
AYF 3 IK 7 PF 19 TNR 1
CF 2 IL 46 PGF 2 TPF 1
CK 1 ILK 1 PIL 2 TSL 4
CL 9 IMF 2 PK 7 TTK 1
CVF 2 IMK 2 PKL 1 TVK 1
DF 4 IPK 2 PL 30 TVL 2
DK 16 IPL 5 PNK 2 TVR 1
DL 11 IQK 2 PPL 2 TWK 1
DMF 2 IR 4 PRL 1 TYF 2
DNR 1 IRF 1 PSF 2 VAL 6
DPK 1 ISF 2 PSK 1 VDL 2
DR 4 ISL 2 PSL 2 VEK 3
DSK 2 ISR 1 PTL 4 VER 2
DSL 4 ITK 1 PTR 2 VF 9
DWL 1 ITL 2 PVK 1 VGF 6
EAF 2 IVL 1 PVL 2 VGL 3
EAR 1 IWL 4 QAL 2 VIR 3
EDK 2 KAL 1 QDF 2 VK 2
EEF 1 KDL 2 QEL 2 VKL 1
EEL 2 KF 2 QF 5 VL 14
EER 1 KGF 1 QGL 2 VMK 2
EF 2 KIL 1 QIR 1 VML 2
EGL 1 KL 4 QK 2 VNL 4
EIF 1 KPL 1 QL 7 VPK 1
EIL 1 KRF 1 QR 1 VPL 4
EK 7 KSL 1 QYK 1 VSF 2
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Figure 2 Distribution of estimated IC50 of di- and tri-peptides with ACE inhibitory activity. The peptides were derived from P. esculenta
proteins. All IC50 values were predicted by LibDock scores according to the equation, LibDock score = 10.063 log(1/IC50) + 68.08.
Table 3 Sequence and frequency of di- and tri-peptides derived from P. esculenta proteins by virtual hydrolysis
(Continued)
EL 16 KTL 1 RAL 1 VSL 3
EML 1 KVF 1 REL 1 VVF 2
ENK 2 LDK 1 RL 3 VVK 2
ENL 6 LEK 1 RPF 1 WAF 2
ER 2 LK 2 RSF 2 WAL 2
ESK 1 LMK 1 RTL 1 WCF 2
ETL 3 LR 1 SAL 4 WF 6
EVK 1 LSK 1 SEK 1 WGK 2
EVL 4 MAL 8 SF 20 WL 8
FFK 1 MF 16 SGF 4 WML 2
FK 1 MFK 1 SGL 2 WNF 2
FWR 1 MFR 1 SHL 2 WPF 2
GAL 2 MGF 2 SIF 2 WQK 2
GF 12 MGL 2 SIK 2 WR 1
GGL 4 MIK 2 SIL 4 WTR 1
GGR 2 MIL 2 SK 6 WWF 2
GK 6 MK 10 SL 50 YAL 1
GKF 1 MKF 2 SNL 3 YF 7
GL 29 ML 16 SPF 2 YIF 2
GLR 1 MPL 1 SPL 2 YIK 1
GNL 2 MR 4 SQL 2 YK 4
GR 3 MSK 2 SR 2 YL 8
GSL 2 MSL 10 SS 2 YPL 2
GTL 4 MTK 2 SSF 6 YS 2
GTR 2 MTL 2 SSL 2 YSK 3
GVK 1 MVK 2 STF 2 YTL 2
GWL 2 NAL 2 STK 1 YVR 1
The enzymes used in virtual hydrolysis are pepsin, trypsin, and a mixture of pepsin and trypsin.









Figure 3 Proportions of C-terminal amino acids for di- and
tri-peptides with estimated IC50 less than 50 μM.
Table 5 Estimated and measured log(1/IC50) of the nine
synthesized peptides derived from P. esculenta
Peptide Estimated log(1/IC50) Measured log(1/IC50) Error
GYF 4.49 4.31 ± 0.02 0.18
FK 4.79 4.27 ± 0.01 0.52
WAL 4.95 4.38 ± 0.04 0.57
QF 4.44 4.21 ± 0.03 0.23
AYF 4.83 4.18 ± 0.01 0.65
EL 3.19 3.43 ± 0.02 −0.24
GLR 4.07 3.61 ± 0.02 0.46
HK 3.53 3.86 ± 0.01 −0.33
ILK 4.09 3.72 ± 0.03 0.37
Table 4 Di- and tri-peptides derived from P. esculenta







WNF 0.12 YIF 13.1 DSL 27.9
HKF 0.42 RPF 13.3 IR 28.9
WCF 0.47 APF 13.4 TGF 29.5
WPF 0.85 REL 13.7 NWL 30.7
WWF 1.18 YK 13.9 FFK 30.9
YVR 1.45 AEF 14.1 GYF 32.2
NRF 1.71 AYF 14.7 ISF 32.3
TYF 1.75 KTL 14.8 FK 33.2
IHR 2.06 WGK 14.9 SPF 33.4
WML 2.15 DWL 14.9 VML 33.7
WAF 3.27 SSF 15.0 KPL 36.1
IWL 5.22 NSF 15.4 ISL 36.5
RSF 5.44 VKL 16.1 QF 36.7
IRF 5.72 MAL 16.3 TML 36.9
CVF 7.15 NR 17.0 QEL 37.0
YIK 7.33 MTL 17.1 MKF 38.0
MGF 7.38 IMF 17.5 YAL 38.6
YF 7.48 WR 17.7 EEF 40.4
KRF 8.11 ER 18.1 IGR 40.5
SR 9.05 AEL 19.4 TEF 41.1
GNL 9.09 QDF 19.5 TTK 41.6
GKF 9.51 YTL 19.7 SGF 41.6
WTR 10.2 PIL 19.9 KVF 42.0
PRL 10.2 KDL 20.2 SIL 43.0
SYL 10.4 SVF 20.8 EVL 43.7
WF 10.6 YSK 21.5 DMF 46.6
IIL 10.8 VVF 22.5 RTL 46.9
WAL 11.3 ITK 22.6 QAL 47.0
AQF 11.5 DR 23.4 TPF 47.0
RAL 11.8 WQK 23.9 HSL 47.1
PGF 12.2 PKL 24.9 NAL 47.1
NVL 12.7 EIF 25.2 SHL 48.0
HTL 13.1 VGF 27.8 STF 49.4
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pepsin hydrolysis, and C-terminal Lys and Arg are formed
by trypsin reaction. Hydrophobic C-terminal (Phe and Leu)
is dominant in amount and accounts for more than 80%
peptides (44.4% and 36.4%, respectively). There are some
accepted concepts about the structure-activity relationship
of ACE inhibitory peptides, such as that peptides with
hydrophobic amino acid in C-terminus showed a highly
potent ACE inhibitory activity [46]. Highly active peptide in
general should be composed of large, hydrophobic, andaromatic amino acid with a polar functional group in C-
terminus [47]; and the physicochemical attributes of amino
acids such as hydrophobicity, bulkiness, and electronic
properties had impacts on the bioactivity of peptides [48].
Accordingly, benzene ring in Phe can also increase the
bulkiness and bring about the stability of binding between
ACE and peptide and sequentially result in high ACE inhibi-
tory activity.
There are 40 peptides among 99 peptides (40.4%) with
hydrophobic amino acid at N-terminal, 38 peptides with
neutral amino acid at N-terminal (38.4%), and 21.9% pep-
tides with positively or negatively charged amino acid at
N-terminal (Figure 4). N-terminal amino acid of ACE
inhibitory peptides also favors the hydrophobic interactions
with ACE [7,30]. The peptides with hydrophobic amino
acid at N-terminal showing higher ACE inhibitory activity
have some superiority in amount in the present study,
which verified such view.
Conclusions
A virtual method of hydrolysis and screening of ACE
inhibitory peptides with high activity such as IC50 value
< 50 μM was constructed in this work. Ninety-nine (99)
peptides were obtained from 22 proteins of P. esculenta.
Besides, the efficiency and the validity of such method were









Figure 4 Proportions of N-terminal amino acids for di- and tri-
peptides with estimated IC50 less than 50 μM.
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The results demonstrated that the virtual hydrolysis and
screening method is an efficient way that greatly cuts down
the experimental labor to get highly active ACE inhibitory
peptides. Moreover, P. esculenta proteins were proved as a
good resource of ACE inhibitory peptides, which could be a
beneficial ingredient for functional foods or pharmaceuti-
cals against hypertension. Further research on larger anti-
hypertension peptides derived from P. esculenta and in vivo
activity testing will be carried out.
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